Mersana Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $2,293 | $9,245 | $10,701 | $7,698 |
Gross Profit | 1,890 | 8,822 | 10,254 | 7,271 |
EBITDA | -24,268 | -20,578 | -20,481 | -41,656 |
EBIT | -24,671 | -21,001 | -20,928 | -42,083 |
Net Income | -24,268 | -19,306 | -19,544 | -41,656 |
Net Change In Cash | 2,293 | 9,245 | 10,701 | 7,698 |
Free Cash Flow | -21,855 | -32,788 | -34,534 | -46,553 |
Cash | 58,998 | 75,186 | 174,561 | 186,283 |
Basic Shares | 121,424 | 121,424 | 120,614 | 120,521 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $36,855 | $26,581 | $43 | $828 |
Gross Profit | 35,338 | 25,654 | -131,970 | -66,208 |
EBITDA | -169,440 | -203,767 | -168,858 | -86,676 |
EBIT | -170,957 | -204,694 | -169,713 | -87,686 |
Net Income | -171,670 | -207,540 | -169,205 | -88,404 |
Net Change In Cash | 36,855 | 26,581 | 43 | 828 |
Cost of Revenue | -76,990 | 192,743 | ||
Free Cash Flow | -171,050 | -51,560 | -140,636 | -75,169 |
Cash | 174,561 | 280,712 | 177,947 | 255,094 |
Basic Shares | 116,112 | 93,654 | 70,580 | 61,485 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.20 |
2024-03-31 | -$0.16 |
2023-12-31 | -$0.16 |
2023-09-30 | -$0.27 |
